USPTO Deadlines
Application History
37 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 18, 2012 | PC.D | I | PETITION TO DIRECTOR DISMISSED | Loading... |
| Dec 13, 2012 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 13, 2012 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Nov 6, 2012 | INCE | O | ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST | Loading... |
| Oct 17, 2012 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Aug 20, 2012 | TPDR | I | TEAS PETITION TO DIRECTOR RECEIVED | Loading... |
| May 31, 2012 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 12, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 11, 2011 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Jul 11, 2011 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Jul 11, 2011 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Jul 5, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 5, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Feb 14, 2011 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 18, 2011 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Jan 18, 2011 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Jan 18, 2011 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Jan 3, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jan 3, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 1, 2010 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 6, 2010 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Mar 19, 2010 | CHPB | I | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED | Loading... |
| Mar 16, 2010 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Feb 19, 2010 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Oct 2, 2009 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Sep 22, 2009 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 2, 2009 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Aug 19, 2009 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 19, 2009 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Aug 13, 2009 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 13, 2009 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 13, 2009 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 13, 2009 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 13, 2009 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 12, 2009 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 18, 2009 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
| May 18, 2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical additives containing galantamine for use in the manufacture of Tablets, Injections, Aerosols, Gels, Time-Released Products, therapeutic patches, prophylactic patches containing galantamine
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals containing galantamine; Drug delivery agents in the form of capsules that provide controlled release of galantamine together with other pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of galantamine together with other pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of galantamine together with other pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of organophosphate toxicity; Inhalers filled with galantamine; Pharmaceutical preparations containing galantamine acting on the central nervous system; Pharmaceutical preparations and substances containing galantamine for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system toxicity related diseases and disorders; Pharmaceutical preparations containing galantamine for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations containing galantamine for the treatment of inflammatory disorders; Pharmaceutical preparations containing galantamine for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention of organophosphate toxicity; Pharmaceutical preparations for the treatment of organophosphate toxicity; Plant extracts containing galantamine for medical, veterinary and pharmaceutical purposes; Syringes sold filled with galantamine; Therapeutic pharmaceutical for the treatment of organophosphate toxicity
First Use Anywhere:
0
First Use in Commerce:
0
Class 016
Information leaflets concerning pharmaceuticals containing galantamine
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
001
005
016